Strategic leadership Recent leadership changes, including John Rigg’s promotion to chairman, signal a growth-focused governance approach. This presents an opportunity to engage at the executive level with a message that aligns with expanded drug delivery capabilities and scale ambitions.

Expansion in gene therapy Active participation in ASGCT and emphasis on drug delivery expertise suggest a growing interest in gene and cell therapy applications. Target collaborations around specialized microspheres and surface modification for biomolecule conjugation could meet this demand.

CDMO capabilities Phosphorex positions as a drug delivery-focused CDMO with custom microsphere solutions, encapsulation, and bioconjugation services. This opens doors for partnering on custom formulations, scalable production, and regulatory-compliant manufacturing for clients in biotech and pharma.

Financial grounding Revenue is in the sub-$1M range with lean operations (very small employee count). Potential sales approach should emphasize flexible engagement models, pilot programs, and low-overhead collaborations to de-risk early partnerships.

Industry fit Core competencies in polymer/nanosphere technology, fluorescent/phosphorescent particles, and surface-modified spheres align with markets needing sensitive assays, imaging, and targeted drug delivery. Position offerings to biotech, diagnostics, and research institutions pursuing advanced analytics and therapeutics.